The latest update is out from CervoMed ( (CRVO) ).
On March 10, 2025, CervoMed Inc. announced positive results from the first 16 weeks of the extension phase of its Phase 2b RewinD-LB clinical trial for neflamapimod, aimed at treating dementia with Lewy bodies. The new batch of neflamapimod capsules showed improved plasma drug concentrations and significant improvements in clinical outcomes compared to old capsules and placebo, suggesting potential to alter the disease course. This development marks a significant step forward in the treatment of DLB, with the company planning to engage with regulatory authorities for Phase 3 trials.
More about CervoMed
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The company is particularly engaged in the development of neflamapimod for treating dementia with Lewy bodies.
YTD Price Performance: -0.90%
Average Trading Volume: 271,993
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $18.24M
For an in-depth examination of CRVO stock, go to TipRanks’ Stock Analysis page.